Pharvaris NVPHVS
Price$31.01

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Free Cash Flow -$161.2MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%

Returns

-61.8%ROE
-58.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Net Debt-$290.8Mnet cash position
Cash & Equivalents$291.7M

Quality Metrics

Piotroski F-Score3 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Diluted EPS
'21'22'23'24'25
FY2025: $-2.97

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Deucrictibant Development$00.0%
View details

NDA submission for deucrictibant IR on-demand treatment on track for 1H 2026.

Financials converted at 0.8513 from EUR.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.